Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on paediatrics and women’s health, announces a promotional agreement with CutisPharma, Inc., a Woburn, Massachusetts based company. The partnership will include the promotion of FIRST - Progesterone VGS, vaginal suppository compounding kits.

Beginning early July, 2011, Centrix Pharmaceutical sales representatives will promote FIRST - Progesterone VGS compounding kits from CutisPharma, Inc. in physician offices, clinics, and hospitals who specialize in obstetrics and gynaecology in addition to retail pharmacies nationwide.

The product line includes FIRST - Progesterone VGS 25, 50, 100, 200, and 400. The kits are made for one patient and include pre-weighed progesterone, and suppository base, and a unique, patented disposable suppository mould for preparation, dispensing, and storage of the suppositories, all in one unit that increases patient compliance, and ease of use.

FIRST - Progesterone VGS saves dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared in the conventional way using a metal suppository mould or polystyrene shells. A single NDC number assigned for the entire kit facilitates the third party reimbursement process, and reduces audit-related adjustments.

CutisPharma, Inc. focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry.